Vericel previews preliminary 2025 financial results

Vericel Corporation filed a report stating it will participate in the 44th Annual J.P.

Rhea-AI Filing Summary

Vericel Corporation filed a report stating it will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, with a presentation scheduled for January 14, 2026, at 11:15 a.m. Pacific Time. In connection with the conference, the company issued a January 13, 2026 press release that provides preliminary, unaudited financial information for full-year 2025.

The press release includes estimates of Vericel’s 2025 revenue, net income, gross margin percentage, adjusted EBITDA margin, and its cash and investments balance as of December 31, 2025, along with additional financial and business updates. The company emphasizes that these figures are preliminary, have not been audited or reviewed by PricewaterhouseCoopers LLP, and may change, so stockholders are cautioned not to place undue reliance on them.

Insights

Equity research analyst

Vericel is furnishing unaudited preliminary 2025 figures tied to a major conference appearance.

Vericel is using its appearance at the 44th Annual J.P. Morgan Healthcare Conference to share preliminary 2025 financial data, including revenue, net income, gross margin, adjusted EBITDA margin, and year-end cash and investments. This positions the company to frame its recent performance directly to investors and industry stakeholders attending the event.

The disclosure is explicitly labeled as preliminary and unaudited, and the company notes that its financial statements for the year ended December 31, 2025 are not yet finalized. PricewaterhouseCoopers LLP has not audited or reviewed the figures, and Vericel warns that actual results may differ materially, urging stockholders not to place undue reliance on the estimates.

The information is furnished rather than filed under the Exchange Act, which limits its use in certain legal contexts. Investors may look to the forthcoming audited year-end financial statements for confirmation of these preliminary indicators once the company completes its year-end reporting process.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What did Vericel (VCEL) disclose in this 8-K filing?

Vericel disclosed that it issued a January 13, 2026 press release containing preliminary, unaudited financial and operating estimates for full-year 2025, including revenue, net income, margins, cash and investments, and other business updates.

Why is Vericel (VCEL) releasing preliminary 2025 financial results?

Vericel released preliminary 2025 financial information in connection with its participation in the 44th Annual J.P. Morgan Healthcare Conference, where it plans to discuss its operating and financial performance along with business updates.

Are Vericel’s preliminary 2025 results audited?

No. The company states that the preliminary 2025 figures are estimated, preliminary and unaudited. Its financial statements for the year ended December 31, 2025 are not yet finalized, and PricewaterhouseCoopers LLP has not audited, reviewed, examined, compiled, or applied agreed-upon procedures to the data.

What caution does Vericel (VCEL) give about its preliminary 2025 data?

Vericel explains that the preliminary data are subject to change and that actual results may differ materially from the estimates, so stockholders should not place undue reliance on the preliminary figures disclosed in the press release.

What specific 2025 metrics does Vericel’s press release address?

According to the report, the press release includes estimated full-year 2025 revenue, preliminary net income, preliminary gross margin percentage, preliminary adjusted EBITDA margin, the estimated cash and investments balance as of December 31, 2025, and additional financial and business updates.

How is the information in Vericel’s Items 2.02 and 7.01 treated under the securities laws?

The company states that, under applicable general instructions, the information in Items 2.02 and 7.01 is furnished and not deemed filed for purposes of Section 18 of the Exchange Act, and is not incorporated by reference into other filings unless specifically referenced.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/13/2026 - 09:11 AM Learn about SEC filing dates

false000088735900008873592026-01-132026-01-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):  January 13, 2026

Vericel Corporation

(Exact name of registrant as specified in its charter)

Michigan	001-35280	94-3096597
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

64 Sidney Street
Cambridge, MA		02139
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code:  (617) 588-5555

Not Applicable

 Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, no par value		VCEL		NASDAQ

Indicate by a check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§240.12b-2 of this chapter). Emerging Growth Company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

Vericel Corporation (the “Company”) will participate in the 44^th Annual J.P. Morgan Healthcare Conference in San Francisco, California, which is being held on Wednesday, January 14, 2026, at 11:15 a.m. Pacific Time.  In connection with its participation in the conference, on January 13, 2026, the Company issued a press release, which includes estimates of operating and financial results, including its estimated, preliminary and unaudited full-year revenue for fiscal year 2025, preliminary and unaudited net income for 2025, preliminary and unaudited 2025 gross margin percentage, preliminary 2025 adjusted EBITDA margin, its estimated cash and investments balance as of December 31, 2025, and additional financial and business updates.

Because the Company’s financial statements for the year ended December 31, 2025, have not been finalized or audited, these preliminary statements regarding the Company’s operating and financial results as of and for the year ended December 31, 2025, are subject to change and the Company’s actual results as of the end of this period may differ materially from this preliminary estimate.  Accordingly, stockholders should not place undue reliance on this preliminary estimate.  A copy of the Company’s January 13, 2026, press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”).

Item 7.01. Regulation FD Disclosure.

​

The information set forth in Item 2.02 of this Report is incorporated into this Item 7.01 by reference.

The preliminary financial data included in this Current Report on Form 8-K has been prepared by, and is the responsibility of, the Company’s management.  PricewaterhouseCoopers LLP has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data.  Accordingly, PricewaterhouseCoopers LLP does not express an opinion or any other form of assurance with respect thereto.

In accordance with General Instructions B.2 and B.6 of Form 8-K, the information included in Item 2.02 and Item 7.01 of this Report shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.		Description
99.1		Press Release, dated January 13, 2026, titled “Vericel Announces Preliminary 2025 Financial Results and Business Updates”
104 *		Cover Page Interactive Data File (embedded within the Inline XBRL)

* Furnished herewith

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press Release, dated January 13, 2026, titled “Vericel Announces Preliminary 2025 Financial Results and Business Updates”
104 *		Cover Page Interactive Data File (embedded within the Inline XBRL)

* Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Vericel Corporation
Date: January 13, 2026	By:	/s/ Sean C. Flynn
		Name: Sean C. Flynn
		Title: Chief Legal Officer